Replies to post #76039 on Biotech Values

[rkrw]

You could add MDV3100 for prostate ca going into p3. I have my doubts based on the reported seizures. Arena's Lorcaserin.
On the other side AUXL partnered with Pfizer ex-US and no plans to partner US.

[genisi]

Late-Stage Products Looking for a Home

Criteria for inclusion:
a) Program is in phase-3 or beyond and is non-partnered.
b) Company does not have enough cash to bring the product to market.

Edits:Added - MDVN, ARNA; Removed - AUXL (partnered with Pfizer ex-US and no plans to partner US)

  
  
  Stock    Product          Stage                   Comments        
 -----    ---------------  ---------------------   -----------------------------        
 ARNA     Lorcaserin       Phase 3                 Obesity  
 BPAX     Libigel          Phase 3 ~2010 Submit    Adequate Safety?        
 CHTP     Droxidopa        Pivotal Phase III       Orthostatic hypotension.  Results expected 02/09.  
 CRGB     Abiraterone      Phase 3                 Prostate cancer  
 DYAX     DX-88 for HAE    BLA filed 9/24/08       (CABG indication partnered w CBST)     
 GNVC     TNFerade         Pivotal Phase III       Pancreatic cancer  
 JAV      Dyloject         Phase III               Approved in UK.  Post operative Pain (injectable)      
 JAV      Ketamine         Phase III               Acute moderate-to-severe pain (intranasal) 
 MDVN     MDV3100          Phase III in H2:09      castration-resistant prostate cancer 
 OREX     Contrave         Phase 3                 Obesity  
 OXGN     Zybrestat        Phase 3                 Anaplastic thyroid cancer     
 Pharming Rhucin           Pre-BLA                 Rejected in EU   
 Protalix prGCD            Phase III               Gaucher's disease. Not enough cash for a commercial infrastructure    
 RPRX     Proellex         Phase 3                 Uterine fibroids  
 SVNT     Puricase         BLA filed               Treatment refratory gout 
 

Procedure for Updating Table

1. Copy the text in this post into a word processor.

2. Using a monospace font (e.g. Courier) to facilitate tabular
alignment, make your additions and modifications, inserting
them in the table in alphabetical order. NOTE: use spaces
rather than tab characters.

3. Add a brief note in the “Edits:” line atop the table to
describe your changes.

4. Insert the iHub formatting directives: Put [ pre ] at the
beginning of the table without the surrounding spaces, and
put [ /pre ] at the end of the table without the surrounding
spaces.

5. Post your text as a reply to this message.

Thank you for your cooperation.